Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20272423 | 0.75 | CCR1 (0.40) | — | |
| SCHEMBL18878954 | 0.71 | GRM1 (0.33) | — | |
| SCHEMBL16381310 | 0.69 | NR4A2 (0.48) | NR4A2NCF1ALDH1A1TSHRNOS1 | |
| SCHEMBL13586024 | 0.68 | PI4KA (0.50) | NR4A2NCF1ALDH1A1TSHRNOS1 | |
| SCHEMBL9615205 | 0.67 | TDO2 (0.33) | TDO2HSD17B10 | |
| SCHEMBL8874949 | 0.67 | AURKA (0.35) | NCF1TDO2NOS1 | |
| SCHEMBL313921 | 0.64 | KDM4E (0.41) | TDO2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL6585704 | 0.62 | NCF1 (0.41) | NR4A2NCF1TDO2ALDH1A1TSHR | |
| SCHEMBL659651 | 0.61 | MEN1 (0.38) | ALDH1A1 | |
| SCHEMBL966279 | 0.61 | DYRK1A (0.55) | NR4A2NCF1ALDH1A1TSHRNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-5616590-A | FUSED THIADIAZOLE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0690061-A1 | Substituted pyridobenzothiadiazoles process and intermediates for their preparation and their use as microbicides | CIBA-GEIGY AG (CH) | 1996-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | NR4A2 838/4885NCF1 959/4885TDO2 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.